EMA consults on tackling cross-contamination at shared drug manufacturing facilities
This article was originally published in SRA
Executive Summary
The European Medicines Agency is inviting feedback on a draft guideline that explains how companies that make different medicinal products at shared manufacturing facilities should review and evaluate pharmacological and toxicological data of individual products to tackle cross-contamination issues1.